With blockbuster drugs coming off patent, rising
research and development costs and profit margins
growing ever slimmer, biotechnology and pharmaceutical
companies are feeling the pressure to find every
business advantage they can. One of the symptoms
of that pressure has been a kaleidoscope of innovative
business decisions. While this momentum ultimately
strengthens a company’s position, transformations
inevitably create uncertainty and challenges as companies
grapple with reinventing their operating model
and business processes.